NAD+ precursor vitamin B3 analogue. First orally bioavailable NAD+ booster with human clinical trial data. Studied for cardiovascular health, neuroprotection, metabolic function, and healthy aging.
Plasma NR brief; measured as sustained NAD+ elevation lasting hours-days
SKUs
2
Evidence
Moderate Evidence
Nicotinamide riboside (NR) is a form of vitamin B3 and a direct precursor to NAD+. It is one of the primary compounds studied for raising cellular NAD+ levels in humans. It has a body of human clinical trial evidence — more than many other longevity supplements — showing it reliably elevates blood NAD+ levels. Whether that elevation translates into meaningful health outcomes is still being established.
NAD+ Elevation Research
Multiple human trials have confirmed that oral NR supplementation raises blood NAD+ and its metabolites. A commonly cited trial (ChromaDex-sponsored, published in Nature Communications) showed approximately 40-60% increases in blood NAD+ metabolites with doses of 100-300mg twice daily.
Cardiovascular Research
A small randomized trial in healthy middle-aged and older adults showed NR supplementation reduced aortic stiffness — a marker of cardiovascular aging — and lowered blood pressure. Larger trials are underway to confirm these findings.
Muscle and Physical Function
Human trials have examined NR for muscle NAD+ content, mitochondrial function, and physical performance. Some studies show increases in muscle NAD+ and improvements in endurance capacity, though not all trials show significant functional benefit.
Neurological Applications
Early research is examining NR for neurodegenerative conditions. A trial in Parkinson's disease patients showed NR raised brain NAD+ levels as measured by MRI spectroscopy and improved mitochondrial function in blood cells.
Consistently raises blood NAD+ metabolites in human trials — one of the most reliably confirmed findings.
Small trial data suggest reductions in aortic stiffness and blood pressure.
Muscle NAD+ content increases with supplementation in some studies.
Parkinson's trial showed brain NAD+ elevation and mitochondrial improvements.
Large randomized trials with clinical endpoints are still ongoing.
While NR reliably raises NAD+ levels, whether raised NAD+ levels translate into clinical benefits has not been confirmed in large trials. Many positive findings come from small studies. Some of the foundational research has been funded by the manufacturer (ChromaDex). The optimal dose and long-term effects are not fully established. NR is a supplement, not an FDA-approved drug.
NAD+ cannot be taken as a pill in a way that easily reaches cells — it is a large charged molecule that does not pass through cell membranes easily. The body needs to build it from precursors. Nicotinamide riboside is one of the most efficient precursors — it enters cells through specific transporters and is rapidly converted to NAD+ through a two-step process. This makes it an effective way to raise intracellular NAD+ without the need for IV administration. Once inside the cell, the additional NAD+ supports mitochondrial energy production, sirtuin activation, and DNA repair — all of the same pathways that direct NAD+ supplementation targets.
NR has a good safety record in human trials. It is generally well-tolerated, with minor and infrequent side effects including mild nausea and flushing. Some people notice increased sweating, which is thought to be related to NAD+ metabolism byproducts. It is sold as a supplement and is widely available. No serious adverse effects have emerged in trials up to 300mg twice daily. Long-term safety beyond the periods studied in trials is not established.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
250–1000mg/day oral; 300mg and 1000mg most studied doses in human trials
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Nicotinamide Riboside Elevates NAD+ Levels in Healthy Humans: First Clinical Trial
Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.